Introduction
============

On the global scale, hepatocellular carcinoma (HCC) is a major contributor to both cancer incidence and mortality. HCC is the fifth most common malignant tumor and the second most common cause of cancer deaths worldwide, with China accounting for over 50% of the world's burden.[@b1-ott-11-1861] Although several advances in HCC prevention, early detection, and diagnosis are efficacious and could reduce the incidence and mortality of HCC, the 5-year survival rate remains unsatisfactory.[@b2-ott-11-1861] Like other cancers, HCC is considered as a heterogeneous disease in which gene aberrations, cellular context, and environmental influences concur to tumor initiation, progression, and metastasis.[@b3-ott-11-1861] Recently, many studies have demonstrated that multiple genes and cellular pathways participate in the occurrence and development of HCC;[@b4-ott-11-1861] however, the precise molecular mechanisms underlying HCC progression is not clear. Therefore, it is important to investigate the target molecules and molecular mechanisms underlying the development and progression of HCC for developing more effective diagnostic and therapeutic strategies.

The high-throughput platforms, such as microarrays, for analysis of genetic alteration during tumorigenesis, are increasingly valued as promising tools in medical oncology research.[@b5-ott-11-1861]--[@b7-ott-11-1861] In the last decade, microarray technology was used to investigate gene expression profiling in HCC carcinogenesis. Recently, microarray technology combining bioinformatics analysis has allowed the comprehensive identification of hundreds of differentially expressed genes (DEGs) involved in the development and progression of HCC, due to their ability to quickly process huge datasets. The reported studies showed that the identification of distinct gene expression signatures and their usefulness as molecular markers played important role in the prediction of HCC occurrence, progression,[@b8-ott-11-1861] and clinical outcomes such as survival, metastasis, and recurrence in HCC patients,[@b9-ott-11-1861]--[@b11-ott-11-1861] as well as identification of the candidate drugs for HCC treatment.[@b12-ott-11-1861] In addition, bioinformatic tools have also greatly performed for detection of miRNA targets to make prediction about miRNAs--target gene interactions for HCC.[@b13-ott-11-1861],[@b14-ott-11-1861] In this study, three mRNA microarray datasets and an miRNA dataset were downloaded from Gene Expression Omnibus (<http://www.ncbi.nlm.nih.gov/geo/>), and analyzed to identify DEGs and differentially expressed miRNAs (DEMs) between HCC tissues and non-tumor tissues samples. Subsequently, functional enrichment and network analysis were applied for the identification of DEGs, combined with "mRNA--miRNA" interaction analysis. This work will provide further insight into HCC development at the molecular level and explore the potential molecular targets for new interventional strategies.

Materials and methods
=====================

Microarray data
---------------

Three gene expression profiles (GSE76427, GSE64041, and GSE57957) and the miRNA expression profile of GSE67882 were downloaded from the Gene Expression Omnibus database. The array data of GSE76427 included 115 HCC tissue samples and 52 nontumor samples (percentages of HCC patients with hepatitis B virus infection and cirrhosis were 46% and 54%, respectively). GSE64041 consisted of 60 paired HCC and nontumor liver tissue samples (all the samples from an unselected patient population with all tumor stages).[@b15-ott-11-1861] GSE57957 included 39 HCC tissue samples and 39 nontumor samples. The miRNA expression profile of GSE67882 included four HCC tissue samples (hepatitis B virus--infected HCC) and eight nontumor samples (chronic hepatitis B patients with no fibrosis).[@b16-ott-11-1861]

Identification of DEGs
----------------------

The analysis was performed using the Gene Expression Omnibus online tool GEO2R (<http://www.ncbi.nlm.nih.gov/geo/geo2r/>), which can compare two groups of samples under the same experimental conditions and was applied to explore DEGs and DEMs between HCC and nontumor samples.[@b17-ott-11-1861] The adjusted *P*-values (adj *P*-value) were applied to correct for the occurrence of false-positive results using the Benjamini and Hochberg false discovery rate method by default. The \|logFC\| larger than 1 and the adj *P*-value \<0.01 were used as the cut-off criteria.

Gene ontology and pathway enrichment analysis of DEGs
-----------------------------------------------------

The Database for Annotation, Visualization, and Integrated Discovery (DAVID; <http://david.abcc.ncifcrf.gov/>) is an online program that provides a comprehensive set of high-throughput gene functional analysis for researchers to understand biological characteristics.[@b18-ott-11-1861] Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed using DAVID online tool to analyze the DEGs at the functional level; *P*\<0.05 was considered statistically significant.

Protein--protein interaction (PPI) network construction and module analysis
---------------------------------------------------------------------------

The Search Tool for the Retrieval of Interacting Genes (<http://string.embl.de/>) database is an online tool designed to construct a PPI network of DEGs and analyze the functional interactions between proteins. A confidence score ≥0.7 was set as significant. Subsequently, the result was visualized using Cytoscape software (3.5.1). The Molecular Complex Detection was performed to screen modules of the PPI network in Cytoscape. The criteria were set as follows: degree cut-off=2, node score cut-off=0.2, k-core=2, and max depth=100.[@b19-ott-11-1861] Moreover, the DAVID online tool was used to analyze the function and pathway enrichment for DEGs in the modules.

Prediction of miRNA targets
---------------------------

MiRecords (<http://c1.accurascience.com/miRecords/>) is an online integrated resource produced by 11 established miRNA target prediction programs including TargetScan, MicroInspector, RNA22, DIANA-microT, NBmiRTar, miRanda, PicTar, miTarget, PITA, RNAhybrid, and MirTarget2.[@b20-ott-11-1861] The genes predicted by at least four programs were identified as the targets of miRNAs.

Tissue samples
--------------

Ten HCC tissues and matched nontumor samples were collected from patients with HCC who underwent complete surgical resection at the Affiliated Hospital of Binzhou Medical University (Binzhou, China). Informed consent was obtained from all patients, and the study protocol was approved by our institutional review board of the Affiliated Hospital of Binzhou Medical University.

RNA isolation and determination of target gene expression using quantitative real-time polymerase chain reaction
----------------------------------------------------------------------------------------------------------------

Total RNA was purified from hepatic tissue using RNAfast200 Total RNA Extract Kit (Fastgene, Shanghai, China). The cDNA was prepared by RevertAid™ First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA, USA). Real-time reverse transcription-polymerase chain reaction (RT-PCR) was performed using an RT-PCR kit according to the protocols recommended by the manufacturer. An SYBR green-based RT-PCR assay was performed using the sequence detection system (Bio-Rad Laboratories Inc., Hercules, CA, USA). The fold change for each target gene was calculated using the comparative Ct (2^−ΔΔCT^) method. Primers used for amplification are presented in [Table 1](#t1-ott-11-1861){ref-type="table"}.

Results
=======

Identification of DEGs
----------------------

In total, 413, 397, and 488 DEGs were identified from GSE57957, GSE64041, and GSE76427 datasets, respectively, with 106 genes screened out in all three datasets ([Figure 1](#f1-ott-11-1861){ref-type="fig"}). Moreover, all the 106 genes presented identical expression trends in the three datasets. Among the 106 genes, 89 were upregulated and 17 genes were downregulated in HCC tissues compared to nontumor tissues.

GO and KEGG pathway enrichment analysis
---------------------------------------

To further investigate the function of identified DEGs, DAVID was performed to analyze functional and pathway enrichment. The upregulated genes mainly participated in biological processes associated with the oxidation--reduction process. Moreover, four typical KEGG pathways were overrepresented in upregulated genes, including chemical carcinogenesis, drug metabolism-cytochrome P450, tryptophan metabolism, and retinol metabolism ([Table 2](#t2-ott-11-1861){ref-type="table"}). However, no KEGG pathway and GO term were obtained from downregulated genes due to the limited number.

Module selection from the PPI network
-------------------------------------

Based on the information from the Search Tool for the Retrieval of Interacting Genes database, the PPI network of DEGs consisted of 105 nodes and 66 edges (average node degree of 1.26 and average local clustering coefficient=0.313), including 89 upregulated genes and 16 downregulated genes (except SRXN1 gene), as shown in [Figure 2A](#f2-ott-11-1861){ref-type="fig"}. A significant module was obtained from the PPI network of DEGs using plug-ins Molecular Complex Detection, including 9 nodes and 36 edges ([Figure 2B](#f2-ott-11-1861){ref-type="fig"}). The nine hub genes were the abnormal spindle protein homologue (ASPM), aurora kinase S (AURKA), cyclin B2 (CCNB2), cyclin-dependent kinase inhibitor 3 (CDKN3), maternal embryonic leucine zipper kinase (MELK), non-SMC condensing I complex, subunit G (NCAPG), nucleolar and spindle associated protein 1 (NUSAP1), protein regulator of cytokinesis 1 (PRC1), and topoisomerase (DNA) II alpha (TOP2A). Enrichment analysis showed that these hub genes were mainly associated with the mitotic cell cycle process, cell division, and mitotic cell cycle ([Table 3](#t3-ott-11-1861){ref-type="table"}).

Identification of DEMs and target gene prediction
-------------------------------------------------

Twenty-one DEMs were screened out from the GSE67882 datasets, including 9 upregulated and 12 downregulated miRNAs. The \|logFC\| \>2 was used as the cut-off criterion. As shown in [Table 4](#t4-ott-11-1861){ref-type="table"}, miR-664\* and miR-222 were the most significantly upregulated and downregulated miRNAs, respectively. The predicted targets of miRNAs were then obtained from the online tool miRecords database. By comparing the targets of the DEMs, ZBTB41 was found to be a potential target of seven miRNAs, including has-miR-1526, has-miR-142-3p, has-miR-186, hasmiR-222, has-miR-29b, has-miR-494, and has-miR-550. Moreover, ZNF148 and KPNA1 were the potential targets of six miRNAs, respectively. In addition, no target genes were found by hsa-miR-664\*, hsa-miR-425\*, hsa-let-7f-1\*, hsa-miR-1274a, hsa-miR-1260, hsa-miR-1826, hsa-miR-106b, hsa-miR-1246, and hsa-miR-34b\*.

Validation of target genes by real-time quantitative polymerase chain reaction
------------------------------------------------------------------------------

As shown in [Figure 3](#f3-ott-11-1861){ref-type="fig"}, ASPM, ZBTB41, AURKA, TOP2A, and CDKN3 were upregulated about 12-, 9-, 7.5-, 6-, and 5-fold, respectively, in the HCC tissues, compared with the nontumor liver tissues. Besides, NCAPG, PRC1, ZNF148, and MELK were upregulated about 5-, 4.5-, 4-, and 3.8-fold, respectively, in HCC samples. However, CCNB2, NUSAP1, and KPNA1 had no statistically significant changes in the RT-PCR analysis.

Discussion
==========

HCC is a common neoplasia which represents the second leading cause of cancer-related death. Most cases occur in developing countries, with China accounting for over 50% of the world's burden.[@b1-ott-11-1861] Understanding the molecular mechanism of HCC is of critical importance for early detection, diagnosis, and treatment. Recently, the rapidly developing and wide use of microarray and high-throughput sequencing technology has revealed thousands of genetic alterations during the progression of diseases, which provide promising targets for early detection, diagnosis, treatment, and prognosis of tumors.

In this study, based on three mRNA datasets, 106 DEGs were identified using bioinformatic analysis, consisting of 89 upregulated genes and 17 downregulated genes in HCC tissues compared to nontumor tissues. Function annotation showed that the upregulated genes were mainly involved in biological processes associated with the oxidation--reduction process. Moreover, the most significantly enriched pathways of the upregulated DEGs were chemical carcinogenesis, drug metabolism-cytochrome P450, tryptophan metabolism, and retinol metabolism. However, no enrichment results were obtained from downregulated genes. By establishing a PPI, nine key genes were identified, which provide new insights for HCC intervention strategy.

Carcinogenesis is a complex process driven by specific genetic/epigenetic alterations and involving multiple signaling cascades. Increased expression of ASPM has been found in many tumors, including pancreatic cancer[@b21-ott-11-1861] and HCC.[@b22-ott-11-1861] Moreover, ASPM plays an important role in tumor cell proliferation and invasion, characteristics of the tumor stem cell,[@b23-ott-11-1861] as well as in patient's prognosis.[@b22-ott-11-1861],[@b24-ott-11-1861] Interestingly, it was reported that ASPM gene expression is strongly associated with cirrhosis caused by hepatitis, indicating that ASPM may be involved in inflammation.[@b25-ott-11-1861],[@b26-ott-11-1861]

AURKA belongs to the aurora kinase family, which plays a critical role in the regulation of mitotic events such as spindle assembly, function of centrosomes and cytoskeleton, and cytokinesis.[@b27-ott-11-1861],[@b28-ott-11-1861] The deregulated expression of AURKA leads to mitotic progression disorders causing tumors such as gastric cancer,[@b29-ott-11-1861] HCC,[@b30-ott-11-1861] and pancreatic cancer.[@b31-ott-11-1861] In HCC, overexpression of AURKA is closely associated with high-grade, high-stage tumors and poor outcome. Microarray studies indicated that AURKA phosphorylates and stabilizes hepatoma upregulated protein,[@b32-ott-11-1861] a cell cycle regulated gene overexpressed in HCC.[@b33-ott-11-1861] In addition, it was reported that AURKA can be regulated at the transcriptional level by hypoxia and hypoxia-inducible factor-1, which are important in the tumor microenvironment.[@b34-ott-11-1861],[@b35-ott-11-1861] Notably, the GO term enrichment showed that many genes are involved in oxidation--reduction process.

Cyclin B2 (CCNB2), a member of the cyclin family proteins, serves a key role in the progression of G2/M transition by activating CDK1 kinase, and cyclin B2 inhibition induces cell cycle arrest. CCNB2 is overexpressed in many types of tumors including colorectal adenocarcinoma,[@b36-ott-11-1861] breast cancer,[@b37-ott-11-1861] and bladder cancer.[@b38-ott-11-1861] Moreover, CCNB2 overexpression is also associated with tumor aggressiveness and poor clinical outcome. The mechanistic study revealed that overexpressed CCNB2 triggers aurora-A--mediated Plkl hyperactivation, resulting in accelerated centrosome separation and lagging chromosomes. Furthermore, CCNB2 and p53 acting antagonistically can control aurora-A--mediated centrosome splitting and accurate chromosome segregation in normal cells.[@b39-ott-11-1861]

The CDKN3 gene encodes a dual-specificity protein tyrosine phosphatase that dephosphorylates CDK1/CDK2 and other proteins.[@b40-ott-11-1861] CDKN3 is often overexpressed in several human cancers; meanwhile, this overexpression correlates with reduced survival in several types of cancer.

MELK, a cell cycle--dependent protein kinase that belongs to the KIN1/PAR-1/MARK family,[@b41-ott-11-1861] participates in diverse biological processes, including cell cycle, RNA processing, and embryonic development. MELK is also involved in the occurrence, progression, and prognosis of multiple tumors. It has been reported that MELK is overexpressed in HCC tissues and plays an important role in the pathogenesis and recurrence of HCC.[@b42-ott-11-1861]

NUSAP1 is an essential microtubule and chromatin-binding protein that cross-links microtubules during mitosis, modulates the dynamics of kinetochore microtubules, and governs chromosome oscillation.[@b43-ott-11-1861] Moreover, NUSAP1 has been shown to be overexpressed in multiple cancer types and acts as a therapeutic target for HCC and other cancers.[@b44-ott-11-1861]

PRC1 is a microtubule-associated protein involved in cytokinesis and microtubule organization.[@b45-ott-11-1861] In HCC, the PRC1 expression level is higher compared with paired adjacent nontumor samples, in recurrent HCC compared with primary HCC tissues.[@b46-ott-11-1861]

The TOP2A gene is located on chromosome 17 (17q21-q22), encoding a 170 kDa nuclear enzyme that controls DNA topological structure, chromosome segregation, and cell cycle progression.[@b47-ott-11-1861] TOP2A expression has been reported to be a significant prognostic marker for tumor advancement and recurrence and a predictor of poor survival in many cancers. In HCC, TOP2A expression at the mRNA and protein level increased compared with that in nontumor samples.[@b48-ott-11-1861] Moreover, a further study showed that TOP2A overexpression did not arise from TOP2A gene amplification and is significantly associated with HBsAg in the serum, as well as with Ki-67 expression.[@b49-ott-11-1861]

Several studies have shown that dysregulation of miRNAs is responsible for the pathogenesis of multiple cancer types, including HCC. In this study, 21 DEMs were identified in HCC, consisting of 9 upregulated and 12 downregulated miRNAs; miR-664\* was the most significantly upregulated miRNA, while miR-222 was the most significantly down-regulated miRNA. MiR-222 belongs to the miR-221/222 family located on the X chromosome and shares a high degree of homology.[@b50-ott-11-1861] Many researchers have reported the role of miR-222 in tumor development as an oncomiR.[@b51-ott-11-1861] In HCC, it is reported that overexpressed miR-222 enhances cellular invasiveness and motility of HCC cells by activating the AKT pathway.[@b52-ott-11-1861] Furthermore, increased expression of miR-222 correlates with the advanced stage of HCC, degree of tumor differentiation, and shorter disease-free survival of patients.[@b52-ott-11-1861]

Conclusion
==========

In summary, this comprehensive bioinformatic analysis has identified numerous DEGs and DEMs that may be involved in the progression of HCC. The study provides a set of useful molecular targets for future investigation of the mechanisms and selection of biomarkers for HCC. In addition, further molecular biological experiments will be performed by our team to confirm the function of the identified genes in HCC.
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![DEGs were identified in mRNA expression profiling datasets GSE76427, GSE64041, and GSE57957 (online tool: <http://bioinformatics.psb.ugent.be/webtools/Venn/>).\
**Abbreviation:** DEGs, differentially expressed genes.](ott-11-1861Fig1){#f1-ott-11-1861}

![Protein--protein interaction network and the selected module.\
**Notes:** (**A**) Protein--protein interaction network of DEGs (online tool: <http://string.embl.de/>). (**B**) A significant module selected from protein--protein interaction network (Cytoscape software).\
**Abbreviation:** DEGs, differentially expressed genes.](ott-11-1861Fig2){#f2-ott-11-1861}

![mRNA expression of nine hub genes and three miRNA-target genes in samples of HCC tissues and nontumor liver tissues.\
**Notes:** Experiments were repeated three times. \*Significantly different at *P*\<0.05.\
**Abbreviation:** HCC, hepatocellular carcinoma.](ott-11-1861Fig3){#f3-ott-11-1861}

###### 

Primers for target genes

  Gene ID                                  Sequence (5′-3′)
  ---------- ----------------------------- -----------------------------
  *ASPM*     Forward                       TCCTACCATTACCACCTAGT
  Reverse    CTTACATGCGTTTGACCAAGTCACCA    
  *AURKA*    Forward                       GCTGGAGAGCTTAAAATTGCAG
  Reverse    TTTTGTAGGTCTCTTGGTATGTG       
  *CCNB2*    Forward                       CACAGGATACACAGAGAATG
  Reverse    CTTGATGGCGATGAATTTAG          
  *CDKN3*    Forward                       CAGCGATGAAGCCGCCCAGT
  Reverse    TGACAGTTCCCCTCTGGTGCAG        
  *MELK*     Forward                       TGTTTCCCGGTCTCGCTAT
  Reverse    AGAAGCTGTAAGAGTTCTGGGT        
  *NCAPG*    Forward                       GGCTGCTGTCGATTAAGGAG
  Reverse    TTATCATCCATCGTGCGGTA          
  *NUSAP1*   Forward                       CTGTGCTTGGGACACAAA
  Reverse    TTGTCAACTTGAATGGGGTAATAA      
  *PRC1*     Forward                       CCAAACAAGGAAATGCCAGT
  Reverse    CACCGGAAAAGTACCCTCCT          
  *TOP2A*    Forward                       TTCTTGATATGCCCCTTTGG
  Reverse    GCTTCAACAGCCTCCAATTC          
  *ZBTB41*   Forward                       TGATGACACCAGCGATGATGAACAG
  Reverse    ACTCATCTGACATCTCCTCCTCTAGC    
  *ZNF148*   Forward                       CGGTATCTTCAAGCAGCAAGTAACAAC
  Reverse    GTGACTCTAATATGGATGCCGTGGTAC   
  *KPNA1*    Forward                       ACCGAAGATGAAGACAGCAGCATTG
  Reverse    GGAGCCTCACACTGTTGGAAGATG      
  *GAPDH*    Forward                       CAGGAGGCATTGCTGATGAT
  Reverse    GAAGGCTGGGGCTCATTT            

###### 

Functional and pathway enrichment analysis of upregulated genes in HCC

  Term             Description                       Count   *P*-value
  ---------------- --------------------------------- ------- -----------
  GO: 0055114      Oxidation--reduction process      17      3.8E-8
  GO: 0020037      Heme binding                      8       4.2E-6
  GO: 0005634      Nucleus                           8       1.0E0
  GO: 0031090      Organelle membrane                7       3.9E-6
  GO: 0005506      Iron ion binding                  7       9.3E-5
  GO: 0005789      Endoplasmic reticulum membrane    7       2.4E-1
  GO: 0004497      Monooxygenase activity            6       8.4E-6
  KEGG: hsa05204   Chemical carcinogenesis           4       1.8E-2
  KEGG: hsa00982   Drug metabolism-cytochrome P450   3       8.1E-2
  KEGG: hsa00380   Tryptophan metabolism             6       7.2E-6
  KEGG: hsa00830   Retinol metabolism                5       1.0E-3

**Abbreviations:** GO, gene ontology; HCC, hepatocellular carcinoma; KEGG, Kyoto Encyclopedia of Genes and Genomes.

###### 

Functional and pathway enrichment analysis of nine hub genes

  Term          Description                  Count   *P*-value
  ------------- ---------------------------- ------- -----------
  GO: 1903047   Mitotic cell cycle process   8       1.92E-07
  GO: 0000278   Mitotic cell cycle           8       2.31E-07
  GO: 0051301   Cell division                7       3.73E-07
  GO: 0030261   Chromosome condensation      3       0.00031
  GO: 0000280   Nuclear division             5       0.000707
  GO: 0015630   Microtubule cytoskeleton     6       0.000558
  GO: 0072687   Meiotic spindle              2       0.000558
  GO: 0005819   Spindle                      4       0.00152
  GO: 0044430   Cytoskeletal part            6       0.00152
  GO: 0005874   Microtubule                  4       0.00314

**Abbreviation:** GO, gene ontology.

###### 

Differentially expressed microRNAs in HCC and their targets

  miRNA                                                     Adj *P-value*   LogFC      Target gene (number of total target genes)
  --------------------------------------------------------- --------------- ---------- ----------------------------------------------------------
  hsa-miR-550                                               0.353507        2.45675    TMEM47 TIA1 EDA2R TXNDC13 CROT HCN1 FGF12 KIAA1627 (236)
  hsa-miR-1                                                 0.31072         2.39629    CLCN3 DDX5 ANKRD29 PFTK1 POGK H3F3B BDNF ARHGEF18 (526)
  hsa-miR-378[\*](#tfn4-ott-11-1861){ref-type="table-fn"}   0.032305        2.21661    SUFU (1)
  hsa-miR-494                                               0.436284        −2.00019   RAP1B C5 H3F3B GLIS3 ZNF207 DCP2 CHD9 ZFX (522)
  hsa-miR-146b-5p                                           0.07674         −2.05892   HMBOX1 SFRS6 SYT1 SMAD4 USP3 TRAF6 CCDC117 BCORL1 (279)
  hsa-miR-210                                               0.020936        −2.48626   EFNA3 FAM116A NPTX1 ISCU ACVR1B GPD1L ZNF827 TMEM20 (38)
  hsa-miR-144                                               0.284664        −2.53919   BRPF1 BACH2 NPTX1 SEMA6A ATP2B1 PTGFRN PHTF2 FBXL3 (622)
  hsa-miR-186                                               0.288715        −3.01538   JAG1 MITF OSBPL8 CCNT2 EIF4E PPP1CC PRKCI RAB6A (944)
  hsa-miR-21                                                0.006681        −3.03907   RP2 YAP1 ADNP ARHGEF7 C17 BAHD1 KIAA1012 GLCCI1 (338)
  hsa-miR-142-3p                                            0.07674         −3.05488   MAP3K7IP2 C9 MMD EML4 VAMP3 TARDBP XPO1 CFL2 (242)
  hsa-miR-29b                                               0.000437        −3.65926   HBP1 TUBB2A TFAP2C TRIM37 SPTAN1 TET1 ZDHHC5 (737)
  hsa-miR-222                                               0.412736        −5.80732   CDKN1B ARID1A VAPB POGZ CDC2L6 TMCC1 INSIG1 ZEB2 (309)

**Notes:** A positive logFC value represents that the microRNA is upregulated in HCC, while a negative logFC value represents that the microRNA is downregulated in HCC.

has-miR-378 expression level is low.

**Abbreviations:** FC, fold change; HCC, hepatocellular carcinoma.
